ALAUNOS THERAPEUTICS INC
TCRTNASDAQTrading Snapshot
- Day Range
- $0.95 – $0.98
- 52-Week Range
- $0.96 – $4.59
- Volume
- $5.83B
- Avg Volume
- $5.25B
- Shares Outstanding
- 2.4M
- Next Earnings
- Nov 24, 2026
Fundamentals Snapshot
- Annual Revenue
- $5,000
- Last Q Revenue
- $1,159
- P/E Ratio
- -0.5
- P/S Ratio
- 781.9x
- EPS (TTM)
- $-1.65
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +21.7%
Why Investors Own TCRT
- ✓High-growth profile — revenue up +57.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 56% gross margin and 28% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ALAUNOS THERAPEUTICS INC
TCRT
StockOtter · stockotter.spaceAbout ALAUNOS THERAPEUTICS INC
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., a research and development partnership with The University of Texas MD Anderson Cancer Center, and both a patent licensing and R&D agreement with the National Cancer Institute. Previously known as ZIOPHARM Oncology, Inc., the company adopted its current name, Alaunos Therapeutics, Inc., in January 2022. Its headquarters are located in Houston, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules
Alaunos Therapeutics announces pricing of a public offering of common stock and pre-funded warrants to fund working capital and general corporate purposes.
Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Shares of Alaunos Therapeutics Inc (NASDAQ:TCRT) rose sharply in pre-market trading following a Securities and Exchange Commission filing that showed the company approved and adopted its Second Amended and Restated By-La